<DOC>
	<DOCNO>NCT00445744</DOCNO>
	<brief_summary>This trial study side effect well give cyclophosphamide busulfan follow donor stem cell transplant work treat patient myelofibrosis , acute myeloid leukemia , myelodysplastic syndrome . Giving chemotherapy , cyclophosphamide busulfan , donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus methotrexate transplant may stop happen</brief_summary>
	<brief_title>Cyclophosphamide Busulfan Followed Donor Stem Cell Transplant Treating Patients With Myelofibrosis , Acute Myeloid Leukemia , Myelodysplastic Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate incidence hepatotoxicity condition regimen CY ( cyclophosphamide ) /tBU ( busulfan ) patient receive hematopoietic cell transplant ( HCT ) . SECONDARY OBJECTIVES : I . To determine overall non-relapse mortality day +200 HCT . II . To determine peak bilirubin level day +20 HCT . III . To determine incidence pulmonary toxicity form idiopathic pulmonary syndrome ( IPS ) . IV . To determine rate graft failure . V. To determine time engraftment . VI . To determine rate relapse . VII . To determine incidence severity graft-versus-host disease ( GVHD ) . VIII . To evaluate pharmacokinetics/dynamics BU CY . X . To evaluate pharmacogenomics response , toxicity pharmacokinetics CY/tBU . OUTLINE : CONDITIONING REGIMEN : Patients receive cyclophosphamide intravenously ( IV ) day -7 -6 busulfan IV 3 hour day -5 -2 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell transplant day 0 . POST-TRANSPLANT IMMUNOSUPPRESSION : Patients receive tacrolimus IV orally ( PO ) twice daily day -1 200 taper day 56 methotrexate day 1 , 3 , 6 , 11 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Idiopathic myelofibrosis ( CIMF ) Myelofibrosis develop polycythemia vera essential thrombocythemia Acute myeloid leukemia without antecedent hematologic disorder , disease stage ( complete remission , minimal residual disease , relapse leukemia ) Myelodysplastic syndrome World Health Organization ( WHO ) FrenchAmericanBritish ( FAB ) category , disease stage Less 61 year age transplant unrelated donor , less 66 year age transplant related donor Receiving unmanipulated peripheral blood stem cell human leukocyte antigen ( HLA ) identical 1allelemismatched relate unrelated donor , receive GCSFstimulated bone marrow coenrolled Fred Hutchinson Cancer Research Center ( FHCRC ) protocol 2250 With Karnofsky Performance score &gt; 70 % time pretransplant evaluation Able give inform consent ( &gt; = 18 year age ) , legal guardian capable give consent ( &lt; 18 year age ) DONOR : HLAidentical 1allelemismatched relate unrelated donor ( high resolution type ) DONOR : Undergoing peripheral blood stem cell harvest GCSFstimulated bone marrow harvest ( bone marrow permit part FHCRC protocol 2250 ) DONOR : In good general health , Karnofsky performance score &gt; 80 % DONOR : Able give inform consent ( &gt; = 18 year age ) , legal guardian able give inform consent ( &lt; 18 year age donate related transplant ) Without HLAidentical 1allelemismatched relate unrelated donor With human immunodeficiency virus ( HIV ) positivity active infectious hepatitis Receiving medication know strongly inhibit enzyme CYP450 pathway , , judgment consent provider , safely discontinue duration condition Whose life expectancy severely limited disease hematologic disorder undergo HCT ( HCTcomorbidity index [ CI ] &gt; 3 ) Women pregnant lactating With known hypersensitivity BU CY With hepatic dysfunction evidence total bilirubin AST &gt; 2x upper limit normal , evidence synthetic dysfunction cirrhosis With impaired renal function , evidence creatinine clearance &lt; 50 % expect , creatinine &gt; 2x upper limit normal , dialysis dependence With impaired pulmonary function , evidence pO2 &lt; 70 mm Hg diffuse capacity carbon monoxide ( DLCO ) &lt; 70 % predict pO2 &lt; 80 mm Hg DLCO &lt; 60 % , receive continuous supplementary oxygen With impaired cardiac function , evidence ejection fraction &lt; 35 % active coronary artery disease Unable give inform consent DONOR : Deemed unable undergo stem cell collection , reason DONOR : HIVpositive , hepatitis B C antigenpositive DONOR : Women positive pregnancy test DONOR : Unable give inform consent ( &gt; = 18 year age ) , without legal guardian able give inform consent ( &lt; 18 year age )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>